8-K: Neuraxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results with 50% Revenue Increase

Neuraxis Inc. reported a 50% year-over-year revenue increase for the fourth quarter of 2024, reaching approximately $800 thousand, and a full-year revenue of $2.7 million, up 11% from the previous year.

Summary

• Neuraxis Inc. announced preliminary unaudited results for the fourth quarter and full year of 2024.
• The company's revenue for the fourth quarter of 2024 was approximately $800 thousand, a 50% increase compared to the same period in 2023.
• Full-year revenue for 2024 reached approximately $2.7 million, an 11% increase compared to 2023.
• The company's cash balance as of December 31, 2024, was approximately $3.7 million.
• The company attributes the revenue growth to expanded insurance coverage for its IB-Stim therapy, which now covers approximately 45 million lives, up from 4 million a year ago.
• Neuraxis also received FDA 510(k) clearance for an expanded indication of IB-Stim, now including patients aged 8 to 21 years, and a new Category I CPT code for PENFS procedures.
• The company expects continued robust revenue growth in 2025 and beyond, driven by these factors and the upcoming commercialization of its Rectal Expulsion Device (RED).

Sentiment

Score: 8

Explanation: The document conveys a strong positive sentiment due to the significant revenue growth, expanded insurance coverage, and FDA approvals. The company's outlook for continued growth and reaching cash flow breakeven further supports this positive sentiment.

Positives

• The company experienced a significant 50% revenue growth in the fourth quarter of 2024 compared to the same period in 2023.
• Full-year revenue also increased by 11% compared to the previous year.
• The company has a healthy cash balance of approximately $3.7 million as of December 31, 2024.
• Expanded insurance coverage for IB-Stim to approximately 45 million lives is a major positive.
• The FDA clearance for an expanded age range for IB-Stim is a positive development.
• The introduction of a new CPT code for PENFS procedures should facilitate reimbursement.
• The upcoming commercialization of the RED device is a positive step for future growth.

Risks

• The preliminary financial information is unaudited and subject to change upon completion of the company's normal financial close procedures and audit.
• The company's future performance is subject to various risks and uncertainties, including economic conditions, stock price volatility, public health issues, and regulatory approvals.
• The company's ability to achieve its growth objectives depends on continued expansion of insurance coverage and successful commercialization of new products.

Future Outlook

The company expects continued robust revenue growth in 2025 and beyond, driven by expanding insurance coverage, the expanded indication for IB-Stim, the new CPT code, and the commercialization of the RED device. They also aim to reach cash flow breakeven.

Management Comments

• Brian Carrico, Chief Executive Officer, stated that they are pleased with the continued strong revenue growth in 4Q24.
• He noted that revenues increased approximately 50% in 4Q24, an acceleration compared to the 40% growth achieved in 3Q24.
• He also mentioned that the company successfully achieved its growth objectives for IB-Stim in 2024, building on the foundation that robust, peer-reviewed data, drives insurance expansion, fostering sustainable revenue and margin growth.
• He believes the company is well positioned to achieve its near-term growth objectives with its strengthened balance sheet, including reaching cash flow breakeven.

Industry Context

This announcement reflects a positive trend in the medical technology sector, particularly in neuromodulation therapies. The expansion of insurance coverage and FDA approvals are key drivers for growth in this industry. The company's focus on evidence-based medicine and peer-reviewed studies aligns with industry best practices.

Comparison to Industry Standards

• The 50% revenue growth in Q4 2024 is a strong performance compared to many medical device companies, especially those in the neuromodulation space.
• Companies like Nevro Corp and Boston Scientific, which are larger players in neuromodulation, have seen varying growth rates, but Neuraxis's growth rate is notable for a company of its size.
• The expansion of insurance coverage to 45 million lives is a significant achievement, as reimbursement is a major hurdle for medical device adoption.
• The FDA clearance for an expanded age range for IB-Stim is also a positive development, as it broadens the potential market for the device.
• The introduction of a new CPT code for PENFS procedures is also a positive development, as it should facilitate reimbursement.

Stakeholder Impact

• Shareholders should be positively impacted by the strong revenue growth and positive outlook.
• Employees may benefit from the company's growth and success.
• Customers (patients) will have increased access to the company's therapies due to expanded insurance coverage.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• The company will complete its normal financial close procedures and audit for the year ended December 31, 2024.
• The company will begin commercialization of its Rectal Expulsion Device (RED) in the first quarter of 2025.
• The company will continue to focus on expanding insurance coverage and driving adoption of its IB-Stim therapy.

Key Dates

Keywords

Neuraxis, IB-Stim, PENFS, neuromodulation, revenue growth, medical technology, FDA clearance, insurance coverage, CPT code, Rectal Expulsion Device